Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation After Suffering Alleged Uncontrollable Bleeding Episode

April 20, 2016 – – BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson), as well as several other defendants, in reference to the blood-thinning drug Xarelto. The plaintiff filing this complaint alleges that Xarelto caused him to suffer from an unexpected and dangerous bleeding episode.

Since its initial filing, the plaintiff’s lawsuit has been transferred and consolidated with thousands of other federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The MDL centralizes the lawsuits to a single court in Eastern Louisiana, where they are currently being presided over by The Honorable Judge Eldon E. Fallon. Judge Fallon has been working to facilitate bellwether trial preparations for the cases and has scheduled tentative bellwether trial dates for early 2017.

Among the thousands of Xarelto lawsuits which have been filed up to this point, this complaint is significant in that it involves 90-counts and a plaintiff request for $4.35 million in compensation. Court documentation indicates that the plaintiff alleges that Bayer and Janssen marketed Xarelto misleadingly to consumers as a safe and effective drug option for patients desiring to prevent strokes, and additionally that these defendants neglected to adequately warn the public of dangerous and even life-threatening bleeding side effects which he states have been linked to the drug.

In addition, the man alleges that these manufacturers were very likely aware that the drug they had produced could cause an increased risk of bleeding episodes for those taking it. Clinical studies which were conducted on Xarelto, the plaintiff indicates, also support this allegation. He claims that if the defendants were, in fact, aware of these potential dangers, they acted with negligence by failing to better protect patients with this critically important information. The plaintiff noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

As lawsuit numbers for Xarelto continue to mount and have reportedly surpassed 3,400, many involved believe that they will only continue to grow as time progresses. Attorney Joseph Osborne is, therefore, working to help others who have used Xarelto and who feel that the drug has negatively impacted their health. He encourages affected patients to use the opportunity to investigate their legal rights in the matter fully, as they may be entitled to substantial compensation. To better assist those wanting to further explore their legal rights, Attorney Osborne is currently offering free legal consultations to qualified parties.

To request additional Xarelto lawsuit information, or to ask questions at any time, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009486